TKNO

Alpha Teknova Inc

TKNO, USA

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

https://www.teknova.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TKNO
stock
TKNO

Alpha Teknova (NASDAQ:TKNO) Upgraded at Zacks Research Defense World

Read more →
TKNO
stock
TKNO

Alpha Teknova (NASDAQ:TKNO) Upgraded at Zacks Research MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$9

Analyst Picks

Strong Buy

3

Buy

0

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.47

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-5.90 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-3.98 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-21.69 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.48

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 15.82% of the total shares of Alpha Teknova Inc

1.

UBS Group AG

(2.9642%)

since

2025/06/30

2.

Balyasny Asset Management LLC

(1.8695%)

since

2025/06/30

3.

BlackRock Inc

(1.3114%)

since

2025/06/30

4.

Vanguard Group Inc

(1.2187%)

since

2025/06/30

5.

Roubaix Capital, LLC

(0.8221%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(0.6149%)

since

2025/07/31

7.

CenterBook Partners LP

(0.5788%)

since

2025/06/30

8.

Geode Capital Management, LLC

(0.5584%)

since

2025/06/30

9.

Goldman Sachs Group Inc

(0.5139%)

since

2025/06/30

10.

iShares Russell 2000 ETF

(0.4664%)

since

2025/08/31

11.

Millennium Management LLC

(0.461%)

since

2025/06/30

12.

Bank of America Corp

(0.4287%)

since

2025/06/30

13.

Conestoga Capital Advisors, LLC

(0.3593%)

since

2025/06/30

14.

Conestoga Micro Cap Growth

(0.3247%)

since

2025/06/30

15.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2896%)

since

2025/07/31

16.

State Street Corp

(0.2618%)

since

2025/06/30

17.

Bank of New York Mellon Corp

(0.2162%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(0.2148%)

since

2025/06/30

19.

Fidelity Small Cap Index

(0.1995%)

since

2025/06/30

20.

Northern Trust Corp

(0.1861%)

since

2025/06/30

21.

Renaissance Technologies Corp

(0.1838%)

since

2025/06/30

22.

Marshall Wace Asset Management Ltd

(0.1682%)

since

2025/06/30

23.

iShares Russell 2000 Growth ETF

(0.1641%)

since

2025/08/31

24.

Divisadero Street Capital Management, LP

(0.1474%)

since

2025/06/30

25.

Bridgeway Capital Management, LLC

(0.1401%)

since

2025/06/30

26.

Bridgeway Ultra-Small Company Market

(0.1401%)

since

2025/06/30

27.

Fidelity Extended Market Index

(0.1354%)

since

2025/07/31

28.

Two Sigma Investments LLC

(0.1317%)

since

2025/06/30

29.

iShares Biotechnology ETF

(0.1229%)

since

2025/08/31

30.

Vanguard Russell 2000 ETF

(0.0958%)

since

2025/07/31

31.

State St Russell Sm Cap® Indx SL Cl I

(0.071%)

since

2025/08/31

32.

iShares Nasdaq US Biotech ETF USD Acc

(0.0633%)

since

2025/08/31

33.

Fidelity Nasdaq Composite Index

(0.0588%)

since

2025/07/31

34.

Conestoga Discovery Institutional

(0.0559%)

since

2025/07/31

35.

Extended Equity Market Fund K

(0.0525%)

since

2025/06/30

36.

Schwab Small Cap Index

(0.051%)

since

2025/07/31

37.

NT R2000 Index Fund - NL

(0.0489%)

since

2025/06/30

38.

Fidelity Total Market Index

(0.0458%)

since

2025/07/31

39.

iShares Micro-Cap ETF

(0.045%)

since

2025/08/31

40.

NT R2000 Index Fund - DC - NL - 3

(0.039%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.0946

Latest Release

Date

2025-09-30

EPS Actual

-0.08

EPS Estimate

-0.1

EPS Difference

0.02

Surprise Percent

20%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.